We recently published a list of the 12 Biotech Stocks with the Biggest Upside Potential. In this article, we are going to ...

Fintel reports that on January 22, 2025, Jefferies upgraded their outlook for Crinetics Pharmaceuticals (NasdaqGS:CRNX) from ...

Jefferies has upgraded Crinetics (CRNX) to buy, citing a recent pullback in the stock on investor concerns about Phase 2 data for the company's drug atumelnant. Read more here.

We recently published a list of Billionaire Joseph Edelman’s Top 10 Long-Term Stock Picks. In this article, we are going to ...

SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) today announced that on January 10, 2025, the Compensation ...

Jefferies analyst Dennis Ding upgraded Crinetics (CRNX) to Buy from Hold with an unchanged price target of $55. The firm cites the pullback in ...

Crinetics Pharmaceuticals (NASDAQ:CRNX – Get Free Report)‘s stock had its “buy” rating reissued by research analysts at HC ...

Analyst David Lebowitz from Citi maintained a Buy rating on Crinetics Pharmaceuticals (CRNX – Research Report) and keeping the price target at ...

SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on January 10, 2025, the Compensation Committee of the Board of Directors granted ...

Crinetics Pharmaceuticals Inc (CRNX) stock saw a decline, ending the day at $40.59 which represents a decrease of $-7.91 or -16.31% from the prior close of $48.5. The stock opened at $46.64 and ...

Jefferies upgraded Crinetics Pharmaceuticals stock, moving the rating from Hold to Buy, while maintaining a price target of $55.00. The decision follows a notable decline in share price from $60 to ...